OakChart

Puma Biotechnology Inc

PBYIHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 8:31 AM ET

8.82+0.68 (8.34%)
2026-11-11 14:32 CET
Market cap
420.19 USD m
Revenue, TTM
231.82 USD m
Net income, TTM
23.83 USD m
Free cash flow, TTM
46.07 USD m
EPS diluted, TTM
0.45
P/E
19.39
Compare

Price

PBYI against its 20, 50 and 200-day averages
2050200beatearnings
6.008.0010.00640K1.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PBYIclose 8.8220-day 10.1250-day 9.83200-day 8.028.82

23.3% under 11.50 on 23 Oct 2026. Last 15 sessions, 51.4% high to low

Profile

PBYI
52-week range, 61% of the way up
4.5711.50

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

IndexRUT
Employees179
IPOApr 20, 2012
Beta1.37
ATR, 14d0.61
Rel volume0.04
Short float10.72%
Insider own22.35%
Inst own68.27%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap455.92M
Enterprise Value352.21M
Income23.83M
Sales231.82M
Book/sh2.84
Cash/sh2.10
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees179
IPOApr 20, 2012

Ratios

P/E19.39
Forward P/E-
PEG-
P/S1.97
P/B3.11
P/C4.20
P/FCF9.90
EV/EBITDA9.72
EV/Sales1.52
Quick Ratio2.81
Current Ratio3.03
Debt/Eq0.03
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)0.45
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y0.05% 0.29%
EPS Y/Y TTM-37.15%
Sales Y/Y TTM9.35%
EPS Q/Q-35.43%
Sales Q/Q1.07%
EarningsNov 05 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own22.35%
Insider Trans-1.78%
Inst Own68.27%
Inst Trans2.74%
ROA11.75%
ROE18.20%
ROIC15.80%
Gross Margin73.59%
Oper. Margin11.27%
Profit Margin10.28%
SMA20-12.83%
SMA50-10.31%
SMA2009.92%
Trades-

Technical

Shs Outstand51.69M
Shs Float40.08M
Short Float10.72%
Short Ratio12.03
Short Interest4.30M
52W High11.50 -23.31%
52W Low4.57 92.77%
Volatility8.46% 5.28%
ATR (14)0.61
RSI (14)39.88
Beta1.37
Rel Volume0.04
Avg Volume357.26K
Volume654

Performance

Perf Week-17.50%
Perf Month-12.86%
Perf Quarter1.25%
Perf Half Y23.00%
Perf YTD48.22%
Perf Year69.92%
Perf 3Y151.97%
Perf 5Y151.97%
Perf 10Y-82.50%
Recom3.00
Target Price6.00
Prev Close8.14
Price8.82
Change %8.34%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 28, 2021UpgradeCCitigroupNeutral → Buy$11+24.7%
Jun 25, 2020ResumedBBofA/MerrillUnderperform$9+2.1%
Oct 08, 2019DowngradeGGoldmanNeutral → Sell$24 → $8-9.3%
May 10, 2019DowngradeCCitigroupBuy → Neutral$24+172.1%
May 10, 2019DowngradeCCantor FitzgeraldOverweight → Neutral$57 → $20+126.8%
Jan 17, 2019InitiatedLLeerink PartnersMkt Perform$21+138.1%
Jan 03, 2019DowngradeGGuggenheimBuy → Neutral
Nov 19, 2018UpgradeGGoldmanSell → Neutral
Nov 02, 2018DowngradeJJP MorganNeutral → Underweight
Nov 02, 2018DowngradeBBofA/MerrillBuy → Underperform

Peers

Mkt cap
TickerCompanyMkt cap
OLMAOlema Pharmaceuticals Inc636.11M
CELCCelcuity Inc3.38B
ZYMEZymeworks BC Inc2.22B
ARVNArvinas Inc449.23M
VSTMVerastem Inc1.11B
KURAKura Oncology Inc730.36M
RIGLRigel Pharmaceuticals826.82M
SNDXSyndax Pharmaceuticals Inc859.77M
FENCFennec Pharmaceuticals Inc371.01M
AZNAstrazeneca plc285.82B

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
WILSON TROY EDWARDDirectorSep 14 '26Sale9.105,00045,50054,750Sep 16 09:13 PM
Cesano AlessandraDirectorSep 14 '26Option Exercise2.9350,000146,500118,850Sep 16 09:06 PM
Cesano AlessandraDirectorSep 14 '26Sale9.1262,150566,99456,700Sep 16 09:06 PM
Cesano AlessandraDirectorSep 14 '26Proposed Sale9.1062,150565,565Sep 14 12:05 PM
WILSON TROY EDWARDDirectorSep 14 '26Proposed Sale9.105,00045,500Sep 14 12:01 PM
AUERBACH ALAN HPresident and CEOJul 06 '26Sale8.2644,058364,0517,261,671Jul 08 08:21 PM
HUNT DOUGLAS MSee RemarksJul 06 '26Sale8.268,46069,905196,841Jul 08 08:19 PM
NOUGUES MAXIMO FChief Financial OfficerJul 06 '26Sale8.269,38677,557230,637Jul 08 08:18 PM
AUERBACH ALAN HOfficerJul 06 '26Proposed Sale8.2644,058364,042Jul 06 04:56 PM
HUNT DOUGLAS MOfficerJul 06 '26Proposed Sale8.268,46069,903Jul 06 04:49 PM
NOUGUES MAXIMO FOfficerJul 06 '26Proposed Sale8.269,38677,555Jul 06 04:44 PM
WILSON TROY EDWARDDirectorJun 12 '26Sale7.2010,80077,74859,750Jun 15 08:16 PM
Stuglik Brian MDirectorJun 12 '26Sale7.208,10058,311113,858Jun 15 08:14 PM
Senderowicz AdrianDirectorJun 12 '26Sale7.2027,000194,31127,000Jun 15 08:13 PM

Held by

AUM
TickerCompanyAUM
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.40B
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
IWMiShares Russell 2000 Index FundAUM: 78.30B
VXFVanguard Extended Market Index ETFAUM: 30.61B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.57B
IWNiShares Russell 2000 Value ETFAUM: 14.17B
DFATU.S. Targeted Value Portfolio-ETF Class SharesAUM: 14.50B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B
BSVOEA Bridgeway Omni Small-Cap Value ETFAUM: 2.44B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.85B

News

latest 14 of 206
  • Puma Biotechnology's Profit Beat And Raised Outlook Mask A Sequential Nerlynx Demand Slide (Earnings Whispers) -8.61% -15.56%
  • Puma Biotech: Q3 Earnings Snapshot (Associated Press)
  • Puma Biotechnology Reports Third Quarter 2026 Financial Results (Business Wire)
  • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Puma Biotechnology's Nerlynx Rebound Faces Proof Test As Rally Lifts The Bar (Earnings Whispers)
  • Loading…
  • Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results (Business Wire)
  • Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Puma Biotechnology Initiates ALISCA-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer (Business Wire)
  • Puma Biotechnology to Present at H.C. Wainwrights 28th Annual Global Investment Conference (Business Wire)
  • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ... (GuruFocus.com) +9.73%
  • Puma Biotech: Q2 Earnings Snapshot (Associated Press)
  • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-050.110-0.11054.10--
2026Q22026-08-060.1600.0400.15656.5053.001
2026Q12026-05-07-0.070-0.170-0.07444.8042.001
2025Q42026-02-260.2600.1900.26159.9068.631
2025Q32025-11-060.1700.0450.17451.9051.002
2025Q22025-08-070.1200.0850.11749.2052.002
2025Q12025-05-080.060-0.0200.06043.1044.553
2024Q42025-02-270.3900.0870.39159.1052.513
2024Q32024-11-070.4100.3330.41380.5070.653
2024Q22024-08-01-0.090-0.130-0.09444.4044.703
2024Q12024-05-02-0.100-0.217-0.10043.8049.053
2023Q42024-02-290.2600.3000.25572.2073.553
2023Q32023-11-020.1200.0770.12156.1057.953
2023Q22023-08-030.0500.0100.04554.6051.734
2023Q12023-05-040.030-0.0750.03052.8049.634
2022Q42023-03-02-0.1200.045-0.12265.7057.064

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.950-2.158-1.950272.3269.67
2020FY-1.520-1.405-1.516225.1225.38
2021FY-0.700-0.866-0.717253.2245.09
2022FY0.0000.1700.000228219.41
2023FY0.4500.4930.454235.6237.05
2024FY0.6200.3000.617230.5223.89
2025FY0.6100.5500.610204.1221.5
2026FY-0.380--226
2027FY-0.200--229
2028FY-0.150--230
2029FY-0.100--231
2030FY-0.000--231

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-08-0711067.2067.2067.20
2026Q4S2026-05-1310063.2063.2063.20
2026Q4S2026-05-0811063.2063.2063.20
2026Q4S2026-02-2711063.5063.5063.50
2026Q4S2025-11-1110058.5058.5058.50
2026Q4S2025-11-1010058.5058.5058.50
2026Q4S2025-11-0910058.5058.5058.50
2026Q4S2025-11-0810058.5058.5058.50
2026Q4S2025-11-0710058.5058.5058.50
2026Q4R2026-08-071100.230.230.23
2026Q4R2026-07-221000.180.180.18
2026Q4R2026-05-081010.180.180.18
2026Q4R2026-02-271100.210.210.21
2026Q4R2026-02-181010.180.180.18

Estimate history

EPS, annual-7.85-2.993-1.95-1.516-0.71700.4540.6170.6140.4548
Period201720182019202020212022202320242025TTM
EPS, quarterly0.4130.3910.060.1170.1740.261-0.0740.1560.112
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual27.685250.991272.26225.11253.155228.031235.637230.468228.371231.82
Period201720182019202020212022202320242025TTM
Sales, quarterly80.54259.07746.00752.43654.47575.45344.81456.50255.056
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual37.59538.32539.20340.08640.08641.17647.64749.10650.40851.689
Period201720182019202020212022202320242025MRQ
Shares, quarterly49.06749.10649.61549.89350.38450.40850.87951.10351.689
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue231.82228.37230.47235.64228.03253.16225.11272.26250.99
Cost of Goods Sold Incl. D&A61.2258.1664.4062.6855.0963.7039.3736.8134.62
Gross Profit170.60170.21166.06172.96172.94189.45185.74235.44216.37
Selling, General and Administrative Excl. Other144.46132.91135.10139.69142.22188.16216.14273.31311.04
Research and Development73.8162.0754.9450.3852.2471.8797.65132.85164.85
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income26.1437.3030.9733.2730.721.29-30.40-37.86-94.67
Interest Expense2.036.6212.4513.3311.5912.8114.0515.0210.98
Unusual Expense0.000.000.000.6219.4617.7416.2025.64-
Net Income Before Taxes28.1035.7824.1022.670.46-28.80-59.79-75.54-113.58
Income Taxes4.274.67-6.181.080.460.320.210.050.00
Consolidated Net Income23.8331.1130.2821.590.00-29.13-59.99-75.59-113.58
Net Income From Continuing Operations23.8331.1130.2821.590.00-29.13-59.99-75.59-113.58
Net Income23.8331.1130.2821.590.00-29.13-59.99-75.59-113.58
EPS (Recurring)0.450.610.620.460.30-0.41-1.23-1.49-2.99
EPS (Basic, Before Extraordinaries)0.470.620.620.460.00-0.72-1.52-1.95-2.99
EPS (Diluted)0.450.610.620.450.00-0.72-1.52-1.95-2.99
EBITDA36.2548.2442.4944.7839.6411.89-23.20-33.06-87.29
Non-Operating Income (Expense)3.995.115.593.360.790.450.862.98-7.92
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.915.496.518.109.3423.8226.7041.8586.94
Price To Earnings Ratio17.9017.906.4258.8319.14----
Price To Sales Ratio2.281.320.650.870.830.491.801.253.08
Gross Margin73.5974.5372.0673.4075.8474.8482.5186.4886.21
Operating Margin11.2716.3313.4414.1213.470.51-13.51-13.91-37.72
Net Margin10.2813.6213.149.160.00-11.51-26.65-27.77-45.25
Shares Outstanding51.6950.4149.1147.6541.1840.0940.0939.2038.33
Market Capitalization420.19420.19149.72205.98193.06123.97407.96340.91776.05

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue55.0656.5044.8175.4554.4852.4446.0159.08
Cost of Goods Sold Incl. D&A15.2012.4710.4223.1312.1712.3010.5613.92
Gross Profit39.8644.0334.3952.3342.3040.1335.4545.16
Selling, General and Administrative Excl. Other34.5836.4438.2235.2232.7333.5031.4731.79
Research and Development18.2818.8919.8016.8415.9115.4513.8615.17
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income5.277.58-3.8317.119.576.643.9813.37
Interest Expense0.000.180.731.121.491.842.182.62
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes6.178.24-3.4317.119.246.173.2712.24
Income Taxes0.220.060.333.670.400.310.29-7.07
Consolidated Net Income5.968.19-3.7513.448.845.862.9719.30
Net Income From Continuing Operations5.968.19-3.7513.448.845.862.9719.30
Net Income5.968.19-3.7513.448.845.862.9719.30
EPS (Recurring)0.110.16-0.070.260.170.120.060.39
EPS (Basic, Before Extraordinaries)0.120.16-0.070.270.180.120.060.39
EPS (Diluted)0.110.16-0.070.260.170.120.060.39
EBITDA7.7310.09-1.3319.7612.299.406.7816.21
Non-Operating Income (Expense)0.900.841.131.121.161.371.461.49
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.601.541.501.281.321.291.601.38
Price To Earnings Ratio17.9016.9910.468.035.424.464.856.42
Price To Sales Ratio2.281.841.431.341.280.720.630.65
Gross Margin72.4077.9276.7469.3577.6576.5477.0676.44
Operating Margin9.5813.42-8.5422.6717.5712.668.6622.62
Net Margin10.8214.49-8.3717.8116.2311.176.4632.68
Shares Outstanding51.6951.1050.8850.4150.3849.8949.6249.11
Market Capitalization420.19412.79325.10299.83267.47170.26146.85149.72

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments99.62100.9795.9481.0790.96102.24120.49165.4281.70
Short Term Receivables53.6532.0148.4940.3532.5325.5428.9021.959.67
Inventories5.518.727.084.537.113.453.172.622.03
Other Current Assets3.905.964.688.339.4314.7113.5813.0113.00
Total Current Assets162.69147.66156.19134.28140.02145.94166.14203.00106.39
Net Property, Plant & Equipment5.565.098.6512.5115.7718.8921.833.964.47
Total Investments and Advances0.002.092.092.593.313.314.324.324.32
Intangible Assets41.3951.1360.8770.6166.1274.1440.4644.4148.35
Deferred Tax Assets5.208.49-------
Other Assets2.830.282.732.071.351.942.153.431.99
Total Assets217.67214.75230.53222.06226.59244.22234.91259.12165.53
Short Term Debt Incl. Current Port. of LT Debt23.8450.8738.804.143.5717.382.620.000.00
Accounts Payable5.065.516.896.4411.1712.0819.1820.6827.69
Other Current Liabilities52.3639.7353.7066.9094.8484.8069.0346.4330.65
Total Current Liabilities81.2596.1199.3877.48109.59114.2590.8467.1158.34
Long Term Debt4.7123.2172.69110.14113.07103.57117.61151.8948.48
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.361.42-------
Other Liabilities0.001.885.0112.836.3832.349.005.825.41
Total Liabilities87.33122.62177.09200.45229.03250.17217.44224.82112.22
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity130.3492.1253.4421.61-2.45-5.9517.4634.3153.30
Total Shareholders Equity130.3492.1253.4421.61-2.45-5.9517.4634.3153.30
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity130.3492.1253.4421.61-2.45-5.9517.4634.3153.30
Total Liabilities & Stockholders Equity217.67214.75230.53222.06226.59244.22234.91259.12165.53
Book Value Per Share2.591.881.120.52-0.06-0.150.450.901.42
Tangible Book Value Per Share1.760.83-0.16-1.19-1.71-2.00-0.59-0.260.13
Full-Time Employees179172185192196267269272318
Price to Book Ratio2.872.115.318.71-49.82-69.1119.6422.7346.68
Return on Assets14.3913.609.540.00-12.37-25.04-30.60-53.49-139.59
Return on Equity27.9741.6057.540.02--1,042.30-292.05-259.28-221.91
Return on Invested Capital23.0426.2517.120.00-26.33-61.46-55.97-61.00-286.85
Quick Ratio1.931.451.501.671.211.251.792.991.79
Current Ratio2.001.541.571.731.281.281.833.021.82

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income23.8331.1130.2821.590.00-29.13-59.99-75.59-113.58
Depreciation10.2110.9411.5211.528.9210.6010.038.087.38
Other Funds (Non Cash)7.496.597.7311.7518.8339.7837.5866.6187.23
Funds from Operations44.7851.8842.4544.8627.7521.25-12.39-0.91-18.96
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.26-10.08-3.54-17.85-43.58-0.6013.1623.28-5.14
Cash from Operating Activities46.0441.8038.9227.01-15.8320.650.7722.38-24.11
Capital Expenditures0.04-0.07-0.06-12.640.000.00-20.05-0.31-0.61
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-26.28-36.12-20.38-6.4914.10-10.8843.455.47-57.01
Purchase of Investments-129.27-108.14-76.23-23.81-4.84-38.07-29.83-127.20-107.50
Sale Or Maturity of Investments102.9972.0255.8517.3318.9427.1973.28132.6750.49
Other Uses0.000.000.000.00-7.000.000.000.000.00
Other Sources0.000.000.00-0.000.000.000.000.00
Cash from Investing Activities-26.25-36.19-20.44-19.127.10-10.8823.405.16-57.62
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.150.130.150.000.000.000.071.357.65
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.150.130.150.000.000.000.071.357.65
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-33.34-44.44-33.330.000.00-3.410.00-60.62100.80
Change in Long Term Debt-33.34-44.44-33.330.000.00-3.410.00-60.62100.80
Issuance of Long Term Debt0.000.000.000.000.0096.598.4419.38100.80
Reduction of Long Term Debt-33.34-44.44-33.330.000.00-100.00-8.44-80.000.00
Net Financing Active Other Cash Flow-0.67-0.89-0.670.0012.22-28.520.00-7.790.00
Other Financing Activities Uses-0.67-0.89-0.670.00-0.28-28.520.00-7.790.00
Cash from Financing Activities-33.86-45.20-33.850.0012.22-31.930.07-67.07108.45
Net Change in Cash-14.07-39.58-15.377.883.50-22.1624.24-39.5326.72
Free Cash Flow46.0741.7338.8626.87-15.8320.650.7322.07-24.71
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow11.457.223.857.66-5.98558.5315.37-
Deferred Taxes & Investment Tax Credit-3.25-7.080.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments108.5893.90103.6499.6296.4898.11
Short Term Receivables32.8334.0626.3353.6533.5625.91
Inventories11.4913.328.695.519.488.59
Other Current Assets4.743.793.603.904.063.96
Total Current Assets157.63145.07142.26162.69143.58136.58
Net Property, Plant & Equipment4.354.524.705.566.453.22
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets34.0936.5238.9641.3943.8346.26
Deferred Tax Assets3.833.833.835.207.087.08
Other Assets2.862.792.962.831.931.78
Total Assets202.77192.74192.70217.67202.86194.92
Short Term Debt Incl. Current Port. of LT Debt0.680.4511.4123.8436.1938.36
Accounts Payable5.063.108.175.066.395.42
Other Current Liabilities46.2346.2740.1652.3640.1635.31
Total Current Liabilities51.9749.8359.7481.2582.7379.10
Long Term Debt4.184.374.554.714.8710.87
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.36--
Other Liabilities0.000.000.000.000.000.23
Total Liabilities56.1554.1964.2887.3387.5990.20
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity146.61138.54128.42130.34115.27104.72
Total Shareholders Equity146.61138.54128.42130.34115.27104.72
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity146.61138.54128.42130.34115.27104.72
Total Liabilities & Stockholders Equity202.77192.74192.70217.67202.86194.92
Book Value Per Share2.842.712.522.592.292.10
Tangible Book Value Per Share2.182.001.761.761.421.17
Full-Time Employees---179--
Price to Book Ratio2.873.212.472.602.531.75
Return on Assets11.7513.7812.5414.3917.4624.23
Return on Equity18.2021.9721.6227.9739.6963.24
Return on Invested Capital3.955.73-2.829.957.365.07
Quick Ratio2.812.642.241.931.621.62
Current Ratio3.032.912.382.001.741.73

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income5.968.19-3.7513.448.845.86
Depreciation2.452.522.582.662.722.76
Other Funds (Non Cash)2.021.951.901.621.461.27
Funds from Operations10.4312.660.7320.9613.039.88
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.15-11.0314.68-6.54-3.344.20
Cash from Operating Activities14.581.6215.4214.429.6914.08
Capital Expenditures0.000.000.000.04-0.03-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-9.717.972.47-27.010.53-11.23
Purchase of Investments-35.91-21.57-24.86-46.94-26.78-21.91
Sale Or Maturity of Investments26.1929.5427.3419.9227.3210.69
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-9.717.972.47-26.980.51-11.25
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.150.000.000.000.000.13
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.150.000.000.000.000.13
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.00-11.12-11.11-11.11-11.11-11.11
Change in Long Term Debt0.00-11.12-11.11-11.11-11.11-11.11
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00-11.12-11.11-11.11-11.11-11.11
Net Financing Active Other Cash Flow0.00-0.22-0.22-0.22-0.22-0.22
Other Financing Activities Uses0.00-0.22-0.22-0.22-0.22-0.22
Cash from Financing Activities0.15-11.34-11.33-11.33-11.33-11.20
Net Change in Cash5.01-1.756.56-23.89-1.14-8.37
Free Cash Flow14.581.6215.4214.469.6614.06
Price to Free Cash Flow11.4510.366.067.356.313.89

Revenue breakdown

Product2024: 195.19M 2025: 204.07M
Royalty2024: 35.28M 2025: 24.30M
United States2024: 230.47M 2025: 228.37M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.72%4.3M40.1M332.13K
2026-10-1511.33%4.5M40.1M319.81K
2026-09-3010.87%4.3M39.2M321.57K
2026-09-1511.01%4.3M39.2M341.56K
2026-08-3110.90%4.3M39.2M321.48K
2026-08-1410.68%4.2M39.0M308.93K
2026-07-3110.57%4.1M39.0M309.82K
2026-07-1510.16%3.9M38.5M296.14K
2026-06-309.34%3.6M38.8M289.31K
2026-06-159.53%3.7M38.8M258.17K
2026-05-299.77%3.8M38.9M301.93K
2026-05-1510.77%4.2M38.9M352.61K
2026-04-3010.67%4.1M38.5M364.57K
2026-04-1510.80%4.2M38.5M404.26K
2026-03-3110.26%3.9M38.4M409.86K
2026-03-1310.71%4.1M38.4M436.77K
2026-02-279.81%3.8M38.4M419.32K
2026-02-139.64%3.7M38.0M403.72K
2026-01-309.10%3.5M38.3M483.40K
2026-01-159.39%3.6M38.3M473.83K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.503.508.000.0026.1360.000.000.992-0.0380.000
call5.001.004.500.006.5480.000.000.923-0.1470.002
call7.500.004.500.008.8750.000.000.771-0.1710.004
call10.000.051.300.141.6154590.000.261-0.0360.004
call12.500.000.800.402.4646040.000.196-0.0460.004
call15.000.003.000.053.0741050.000.169-0.0530.003
call17.500.000.100.072.76010.000.000.072-0.0260.002
put2.500.003.800.000.0000.000.00-0.008-0.0380.000
put5.000.003.800.0014.9030.000.00-0.077-0.1460.002
put7.500.003.600.008.2430.000.00-0.229-0.1700.004
put10.000.104.902.046.9641240.00-0.739-0.0350.004
put12.502.006.503.106.1990.000.00-0.804-0.0450.004
put15.004.508.900.006.7360.000.00-0.831-0.0510.003
put17.507.0011.500.007.4930.000.00-0.928-0.0240.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-06SCHEDULE 13D/ASEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-06-168-KCurrent report2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-12144Filing for proposed sale of securities under Rule 144.SEC
2026-06-12144Filing for proposed sale of securities under Rule 144.SEC
2026-06-12144Filing for proposed sale of securities under Rule 144.SEC
2026-06-12144Filing for proposed sale of securities under Rule 144.SEC
2026-06-12144Filing for proposed sale of securities under Rule 144.SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900612.49K2
2026-080000
2026-0700511.51K3
2026-0600572.75K5
2026-050000
2026-040000
2026-030000
2026-020000
2026-0100321.76K6
2025-120000
2025-110097.23K1

Institutional holders

Manager% owned
ACORN CAPITAL ADVISORS, LLC8.12%
BlackRock, Inc.7.47%
AMERICAN CENTURY COMPANIES INC4.56%
ACADIAN ASSET MANAGEMENT LLC4.04%
LSV ASSET MANAGEMENT3.76%
RENAISSANCE TECHNOLOGIES LLC3.61%
VANGUARD CAPITAL MANAGEMENT LLC3.61%
VANGUARD PORTFOLIO MANAGEMENT LLC3.59%
DIMENSIONAL FUND ADVISORS LP3.01%
GEODE CAPITAL MANAGEMENT, LLC2.58%

Funds

Fund% owned
Avantis U.S. Small Cap Value ETF4.38%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.64%
iShares Russell 2000 ETF2.31%
VANGUARD EXPLORER FUND1.53%
VANGUARD STRATEGIC EQUITY FUND1.06%
Fidelity Small Cap Index Fund0.95%
VANGUARD EXTENDED MARKET INDEX FUND0.86%
iShares Russell 2000 Value ETF0.66%
Small Cap Value Fund0.53%
VANGUARD RUSSELL 2000 INDEX FUND0.49%

OakChart. PBYI. Cached 15 minutes.